One dose of HPV vaccine may prevent cervical cancer

accreditation
iStock

A single dose – rather than the recommended three – of a vaccine against the sexually transmitted disease HPV may be enough to ward off cervical cancer, researchers said Monday.

The findings may lead to simpler delivery and lower costs, possibly increasing the number of young people who get vaccinated, said the report in the journal Cancer Prevention Research.

The HPV vaccine is recommended for girls and boys before they become sexually active, but US research from 2012 showed that only one third of US female teens and fewer than 7% of US boys got the recommended three doses.

"Our findings suggest promise for simplified vaccine administration schedules that might be cheaper, simpler, and more likely to be implemented around the world," said Mahboobeh Safaeian, an investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Maryland.

How the study was done

The study focused on a population of nearly 7 500 women aged 18-25 in Costa Rica. Although all were supposed to get the recommended three doses of the HPV vaccine at different times, about 20% of participants did not.

So researchers analyzed blood samples from a group of 78 who got one dose, compared to groups of 120 to 192 that received two or three doses as planned.

They found that all the women in all three groups had antibodies against virulent strains of HPV, known as 16 and 18.

These antibodies persisted in their blood for up to four years, which is about as long as researchers have expected the vaccine to be effective.

The levels of antibodies also appeared stable over time, even though they were slightly lower in the single dose group, suggesting "these are lasting responses," said the study.

The vaccine used in the study was Cervarix, made by the British pharmaceutical giant GlaxoSmithKline.

"GSK is continuing to review findings from this trial and is committed to ensuring regulatory authorities and public health officials have access to this information," a company spokesman told AFP.

Impact of the findings

Study authors said antibody responses after a single dose have not been evaluated for Gardasil, the quadrivalent HPV vaccine made by Merck that is more widely used in the United States and many other countries.

More research is needed before any formal changes can be decided, but Safaeian said the findings could have far-reaching impact in low income nations.

"Vaccination with two doses, or even one dose, could simplify the logistics and reduce the cost of vaccination, which could be especially important in the developing world, where more than 85% of cervical cancers occur, and where cervical cancer is one of the most common causes of cancer-related deaths," she said.

HPV can cause oral, anal, and cervical cancer.

According to the World Health Organization, cervical cancer is the second most common cancer in women worldwide, and causes 500 000 new cases and 250 000 deaths each year.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
Zama zama crackdown: What are your thoughts on West Village residents taking the law into their own hands?
Please select an option Oops! Something went wrong, please try again later.
Results
Authorities should bring in the army already
11% - 2324 votes
Illegal miners can't be scapegoated for all crime
48% - 9939 votes
What else did we expect without no proper policing
37% - 7701 votes
Vigilante groups are also part of the problem
4% - 766 votes
Vote
Rand - Dollar
16.69
-0.2%
Rand - Pound
20.09
-0.1%
Rand - Euro
16.97
-0.1%
Rand - Aus dollar
11.55
+0.0%
Rand - Yen
0.12
-0.1%
Gold
1,762.88
+0.1%
Silver
19.66
-0.7%
Palladium
2,138.50
-0.3%
Platinum
923.00
-0.7%
Brent Crude
93.65
+1.4%
Top 40
64,168
0.0%
All Share
70,967
0.0%
Resource 10
63,227
0.0%
Industrial 25
87,430
0.0%
Financial 15
16,160
0.0%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE